Relay Therapeutics Inc. (RLAY): Price and Financial Metrics


Relay Therapeutics Inc. (RLAY): $18.07

-0.29 (-1.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RLAY POWR Grades

  • RLAY scores best on the Growth dimension, with a Growth rank ahead of 41.27% of US stocks.
  • The strongest trend for RLAY is in Growth, which has been heading down over the past 177 days.
  • RLAY ranks lowest in Momentum; there it ranks in the 4th percentile.

RLAY Stock Summary

  • RELAY THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 7.54% of US listed stocks.
  • RLAY's price/sales ratio is 1,309.52; that's higher than the P/S ratio of 99.65% of US stocks.
  • Revenue growth over the past 12 months for RELAY THERAPEUTICS INC comes in at -98.01%, a number that bests merely 0.79% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to RLAY, based on their financial statements, market capitalization, and price volatility, are IGMS, FATE, NTLA, SRRK, and ARBE.
  • Visit RLAY's SEC page to see the company's official filings. To visit the company's web site, go to relaytx.com.

RLAY Valuation Summary

  • RLAY's EV/EBIT ratio is -6.8; this is 178.16% lower than that of the median Healthcare stock.
  • RLAY's price/sales ratio has moved NA NA over the prior 29 months.

Below are key valuation metrics over time for RLAY.

Stock Date P/S P/B P/E EV/EBIT
RLAY 2022-12-02 1338.8 2.3 -7.8 -6.8
RLAY 2022-12-01 1268.1 2.1 -7.4 -6.4
RLAY 2022-11-30 1325.2 2.2 -7.7 -6.7
RLAY 2022-11-29 1303.1 2.2 -7.6 -6.6
RLAY 2022-11-28 1313.1 2.2 -7.7 -6.6
RLAY 2022-11-25 1328.1 2.3 -7.8 -6.7

RLAY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RLAY has a Quality Grade of C, ranking ahead of 49.22% of graded US stocks.
  • RLAY's asset turnover comes in at 0.111 -- ranking 257th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RLAY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.111 1 -0.620
2021-03-31 0.125 1 -0.215
2020-12-31 0.146 1 -0.191

RLAY Price Target

For more insight on analysts targets of RLAY, see our RLAY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $54.33 Average Broker Recommendation 1.36 (Strong Buy)

RLAY Stock Price Chart Interactive Chart >

Price chart for RLAY

RLAY Price/Volume Stats

Current price $18.07 52-week high $35.36
Prev. close $18.36 52-week low $12.65
Day low $17.60 Volume 720,400
Day high $18.46 Avg. volume 942,408
50-day MA $20.55 Dividend yield N/A
200-day MA $21.86 Market Cap 2.18B

Relay Therapeutics Inc. (RLAY) Company Bio


Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.


RLAY Latest News Stream


Event/Time News Detail
Loading, please wait...

RLAY Latest Social Stream


Loading social stream, please wait...

View Full RLAY Social Stream

Latest RLAY News From Around the Web

Below are the latest news stories about RELAY THERAPEUTICS INC that investors may wish to consider to help them evaluate RLAY as an investment opportunity.

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | November 24, 2022

Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies

In this article, we discuss the top 15 companies in Alphabet Inc (GOOGL)’s investment portfolio. If you want to see more names in this portfolio, check out Alphabet Inc (GOOGL) Investment Portfolio: Top 5 Companies. GV, previously named Google Ventures, is the venture capital investment arm of Alphabet Inc. (NASDAQ:GOOG), which was founded in 2009 […]

Yahoo | November 17, 2022

Investing in Relay Therapeutics Inc. (RLAY) might be a great opportunity, but the stock is a bit undervalued

Relay Therapeutics Inc. (NASDAQ:RLAY) marked $19.02 per share on Wednesday, down from a previous closing price of $19.97. While Relay Therapeutics Inc. has underperformed by -4.76%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RLAY fell by -45.81%, with highs and lows ranging from $36.63 to […]

US Post News | November 10, 2022

H.C. Wainwright Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Relay Therapeutics (RLAY - Research Report), with a price target of $43.00. The company's shares closed last Friday at $20.49.Burns covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, MacroGenics, and BioNTech SE. According to TipRanks, Burns has an average return of -22.7% and a 22.60% success rate on recommended stocks. Currently, the analyst consensus on Relay Therapeutics is a Strong Buy with an average price target of $38.43, representing an 87.55% upside. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a $45.00 price target.

Austin Angelo on TipRanks | November 7, 2022

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on Monday, November 14, 2022 at 10:00 a.m. ET and the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 1:15 p.m. ET.

GlobeNewswire | November 7, 2022

Read More 'RLAY' Stories Here

RLAY Price Returns

1-mo -11.25%
3-mo -42.40%
6-mo 29.07%
1-year -38.75%
3-year N/A
5-year N/A
YTD -41.16%
2021 -26.11%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6687 seconds.